About Solute carrier family 35 member E2B
Solute carrier family 35 member E2B (SLC35E2B) is a protein
from Homo sapiens identified by UniProt accession
P0CK96, 405 residues long.
MolForge cross-references it against 0 known binders and
24 disease associations.
Target properties
| Protein name | Solute carrier family 35 member E2B |
|---|
| UniProt accession | P0CK96 |
|---|
| Gene | SLC35E2B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 405 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (24)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.43
- body mass index · score 0.27
- body fat percentage · score 0.24
- lean body mass · score 0.21
- body weight · score 0.19
- body height · score 0.19
- fat body mass · score 0.18
- total blood protein measurement · score 0.18
- pulse pressure measurement · score 0.15
- lymphocyte count · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P0CK96-F1 | alphafold | PREDICTED | 73.98 | — |
Amino-acid sequence (405 residues)
MSSSVKTPAL EELVPGSEEK PKGRSPLSWG SLFGHRSEKI VFAKSDGGTD ENVLTVTITE TTVIESDLGV WSSRALLYLT LWFFFSFCTL FLNKYILSLL GGEPSMLGAV QMLSTTVIGC VKTLVPCCLY QHKARLSYPP NFLMTMLFVG LMRFATVVLG LVSLKNVAVS FAETVKSSAP IFTVIMSRMI LGEYTGLLVN LSLIPVMGGL ALCTATEISF NVLGFSAALS TNIMDCLQNV FSKKLLSGDK YRFSAPELQF YTSAAAVAML VPARVFFTDV PVIGRSGKSF SYNQDVVLLL LTDGVLFHLQ SVTAYALMGK ISPVTFSVAS TVKHALSIWL SVIVFGNKIT SLSAVGTALV TVGVLLYNKA RQHQQEALQS LAAATGRAPD DTVEPLLPQD PRQHP
Explore Solute carrier family 35 member E2B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets